ProfileGDS5678 / 1419182_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 84% 78% 81% 77% 85% 73% 83% 83% 81% 82% 70% 83% 82% 81% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.1019384
GSM967853U87-EV human glioblastoma xenograft - Control 25.3997978
GSM967854U87-EV human glioblastoma xenograft - Control 35.7660881
GSM967855U87-EV human glioblastoma xenograft - Control 45.3429177
GSM967856U87-EV human glioblastoma xenograft - Control 56.4797885
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.5887973
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.8525583
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.0798383
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.7450781
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.0022782
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.3426570
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.1580683
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.9564282
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.7717481